Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-10-06

AUTHORS

Ikuko Yataba, Noboru Otsuka, Isao Matsushita, Miho Kamezawa, Ichimaro Yamada, Sigeru Sasaki, Kazuo Uebaba, Hideo Matsumoto, Yuichi Hoshino

ABSTRACT

PURPOSE: The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans. METHODS: Study 1: SFPP tape-type patch (2-60 mg) was applied to the lower back for 24 h in healthy adult volunteers. S-flurbiprofen (SFP) plasma concentration was measured over time to examine SFP pharmacokinetics. Study 2: SFPP (20 mg) was applied for 12 h to the affected knee of osteoarthritis (OA) patients who were scheduled for total knee arthroplasty. Deep tissues (synovial tissue and synovial fluid) were collected during surgery to compare SFP concentrations after application of SFPP or a commercially available flurbiprofen (FP) gel-type patch. RESULTS: Study 1: The plasma concentration of SFP was sustained during 24-h topical application of the SFPP, showing a high percutaneous absorption ratio of 51.4-72.2 %. Cmax and AUC0-∞ were dose-proportional. Study 2: After application of the SFPP for 12 h, SFP concentrations in the synovial tissue and synovial fluid were 14.8-fold (p = 0.002) and 32.7-fold (p < 0.001) higher, respectively, than those achieved by the FP patch. CONCLUSIONS: Sustained plasma concentration of SFP and high percutaneous absorption ratio was observed after 24-h topical application of the SFPP. Compared to the FP patch, the SFPP showed superior percutaneous absorption and greater tissue penetration of SFP into the synovial tissue. Greater tissue penetration of the SFPP seemed to be primarily due to its formulation. Thus, SFPP is expected to show higher efficacy for the treatment of knee OA. More... »

PAGES

53-59

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-015-1960-6

DOI

http://dx.doi.org/10.1007/s00228-015-1960-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053196530

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26438533


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Topical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents, Non-Steroidal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flurbiprofen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Healthy Volunteers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoarthritis, Knee", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Synovial Membrane", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transdermal Patch", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yataba", 
        "givenName": "Ikuko", 
        "id": "sg:person.01007646725.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007646725.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Otsuka", 
        "givenName": "Noboru", 
        "id": "sg:person.01055762125.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055762125.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsushita", 
        "givenName": "Isao", 
        "id": "sg:person.014133260061.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133260061.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kamezawa", 
        "givenName": "Miho", 
        "id": "sg:person.01172210525.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172210525.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamada", 
        "givenName": "Ichimaro", 
        "id": "sg:person.0665124056.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665124056.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sapporo Tsukisamu Chuo Orthopedics, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Sapporo Tsukisamu Chuo Orthopedics, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sasaki", 
        "givenName": "Sigeru", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Health Science, Teikyo Heisei University, Ichihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.440938.2", 
          "name": [
            "Faculty of Health Science, Teikyo Heisei University, Ichihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uebaba", 
        "givenName": "Kazuo", 
        "id": "sg:person.0761060035.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761060035.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Integrated Sports Medicine, School of Medicine, Keio University, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26091.3c", 
          "name": [
            "Institute for Integrated Sports Medicine, School of Medicine, Keio University, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Hideo", 
        "id": "sg:person.01012703556.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012703556.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopedics Surgery, School of Medicine, Jichi Medical University, Shimotsuke, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410804.9", 
          "name": [
            "Orthopedics Surgery, School of Medicine, Jichi Medical University, Shimotsuke, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoshino", 
        "givenName": "Yuichi", 
        "id": "sg:person.01167422121.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167422121.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1208/s12249-009-9367-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042774560", 
          "https://doi.org/10.1208/s12249-009-9367-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00167-013-2408-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013794139", 
          "https://doi.org/10.1007/s00167-013-2408-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-10-06", 
    "datePublishedReg": "2015-10-06", 
    "description": "PURPOSE: The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans.\nMETHODS: Study 1: SFPP tape-type patch (2-60\u00a0mg) was applied to the lower back for 24\u00a0h in healthy adult volunteers. S-flurbiprofen (SFP) plasma concentration was measured over time to examine SFP pharmacokinetics. Study 2: SFPP (20\u00a0mg) was applied for 12\u00a0h to the affected knee of osteoarthritis (OA) patients who were scheduled for total knee arthroplasty. Deep tissues (synovial tissue and synovial fluid) were collected during surgery to compare SFP concentrations after application of SFPP or a commercially available flurbiprofen (FP) gel-type patch.\nRESULTS: Study 1: The plasma concentration of SFP was sustained during 24-h topical application of the SFPP, showing a high percutaneous absorption ratio of 51.4-72.2\u00a0%. Cmax and AUC0-\u221e were dose-proportional. Study 2: After application of the SFPP for 12\u00a0h, SFP concentrations in the synovial tissue and synovial fluid were 14.8-fold (p\u00a0=\u00a00.002) and 32.7-fold (p\u00a0<\u00a00.001) higher, respectively, than those achieved by the FP patch.\nCONCLUSIONS: Sustained plasma concentration of SFP and high percutaneous absorption ratio was observed after 24-h topical application of the SFPP. Compared to the FP patch, the SFPP showed superior percutaneous absorption and greater tissue penetration of SFP into the synovial tissue. Greater tissue penetration of the SFPP seemed to be primarily due to its formulation. Thus, SFPP is expected to show higher efficacy for the treatment of knee OA.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00228-015-1960-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "72"
      }
    ], 
    "keywords": [
      "plasma concentrations", 
      "flurbiprofen plaster", 
      "synovial tissue", 
      "topical application", 
      "total knee arthroplasty", 
      "healthy adult volunteers", 
      "greater tissue penetration", 
      "tissue penetration", 
      "osteoarthritis patients", 
      "knee OA", 
      "synovial concentrations", 
      "knee arthroplasty", 
      "plasma pharmacokinetics", 
      "synovial fluid", 
      "adult volunteers", 
      "percutaneous absorption", 
      "pharmacokinetics", 
      "high efficacy", 
      "deep tissues", 
      "tissue", 
      "SFPP", 
      "Study 1", 
      "deep tissue penetration capability", 
      "humans", 
      "patients", 
      "surgery", 
      "arthroplasty", 
      "AUC0", 
      "Cmax", 
      "knee", 
      "volunteers", 
      "efficacy", 
      "treatment", 
      "OA", 
      "concentration", 
      "tissue penetration capability", 
      "plaster", 
      "study", 
      "patches", 
      "ratio", 
      "fluid", 
      "penetration", 
      "purpose", 
      "SFP", 
      "time", 
      "absorption ratio", 
      "absorption", 
      "penetration capability", 
      "formulation", 
      "applications", 
      "capability", 
      "SFPP tape-type patch", 
      "tape-type patch", 
      "flurbiprofen (SFP) plasma concentration", 
      "SFP pharmacokinetics", 
      "SFP concentrations", 
      "application of SFPP", 
      "available flurbiprofen (FP) gel-type patch", 
      "flurbiprofen (FP) gel-type patch", 
      "gel-type patch", 
      "high percutaneous absorption ratio", 
      "percutaneous absorption ratio", 
      "FP patch", 
      "superior percutaneous absorption"
    ], 
    "name": "Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans", 
    "pagination": "53-59", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053196530"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-015-1960-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26438533"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-015-1960-6", 
      "https://app.dimensions.ai/details/publication/pub.1053196530"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_652.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00228-015-1960-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-015-1960-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-015-1960-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-015-1960-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-015-1960-6'


 

This table displays all metadata directly associated to this object as RDF triples.

268 TRIPLES      22 PREDICATES      108 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-015-1960-6 schema:about N09e5b8949b2440099898a233054136d5
2 N1b755748b05a40afb9f8fe539ce1d968
3 N23af7c5088a64db4864c397225394aa6
4 N3167d6ac7d184188a01c001b810dcbc8
5 N34f895712bfb4aa7a9277a8312566540
6 N467fe4b3e4d144a8ab63e2f37aeeec7a
7 N658eed91326c4e908dd5e3ea525b2985
8 N78c9864a542d4a48a203a82c22d7fe4d
9 N80d39d3d1e0d4eb1967753239d58deea
10 N9b651202a74045518af3ef3383cd2e73
11 Na0af97498d0c4c82aaebf4f3aa9c1c84
12 Nad0cf376c348409b81aa73aae6073365
13 Nb47bc7d12a5f4aed8dbae5ef2cedafbe
14 Nc17ed824cf5b4d9884f5d8fb251ea630
15 Nf703805a1a8347f48d6ae0a3f7fc42eb
16 Nfe54a6f261134c2b8ac6800d5594741d
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N4a0860cd8a4c454e98276b34d536145b
20 schema:citation sg:pub.10.1007/s00167-013-2408-0
21 sg:pub.10.1208/s12249-009-9367-2
22 schema:datePublished 2015-10-06
23 schema:datePublishedReg 2015-10-06
24 schema:description PURPOSE: The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans. METHODS: Study 1: SFPP tape-type patch (2-60 mg) was applied to the lower back for 24 h in healthy adult volunteers. S-flurbiprofen (SFP) plasma concentration was measured over time to examine SFP pharmacokinetics. Study 2: SFPP (20 mg) was applied for 12 h to the affected knee of osteoarthritis (OA) patients who were scheduled for total knee arthroplasty. Deep tissues (synovial tissue and synovial fluid) were collected during surgery to compare SFP concentrations after application of SFPP or a commercially available flurbiprofen (FP) gel-type patch. RESULTS: Study 1: The plasma concentration of SFP was sustained during 24-h topical application of the SFPP, showing a high percutaneous absorption ratio of 51.4-72.2 %. Cmax and AUC0-∞ were dose-proportional. Study 2: After application of the SFPP for 12 h, SFP concentrations in the synovial tissue and synovial fluid were 14.8-fold (p = 0.002) and 32.7-fold (p < 0.001) higher, respectively, than those achieved by the FP patch. CONCLUSIONS: Sustained plasma concentration of SFP and high percutaneous absorption ratio was observed after 24-h topical application of the SFPP. Compared to the FP patch, the SFPP showed superior percutaneous absorption and greater tissue penetration of SFP into the synovial tissue. Greater tissue penetration of the SFPP seemed to be primarily due to its formulation. Thus, SFPP is expected to show higher efficacy for the treatment of knee OA.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N4bcdfea986604b38b6eba1062753f971
29 N9f04746bbc5347a993ff1567355f87ca
30 sg:journal.1054337
31 schema:keywords AUC0
32 Cmax
33 FP patch
34 OA
35 SFP
36 SFP concentrations
37 SFP pharmacokinetics
38 SFPP
39 SFPP tape-type patch
40 Study 1
41 absorption
42 absorption ratio
43 adult volunteers
44 application of SFPP
45 applications
46 arthroplasty
47 available flurbiprofen (FP) gel-type patch
48 capability
49 concentration
50 deep tissue penetration capability
51 deep tissues
52 efficacy
53 fluid
54 flurbiprofen (FP) gel-type patch
55 flurbiprofen (SFP) plasma concentration
56 flurbiprofen plaster
57 formulation
58 gel-type patch
59 greater tissue penetration
60 healthy adult volunteers
61 high efficacy
62 high percutaneous absorption ratio
63 humans
64 knee
65 knee OA
66 knee arthroplasty
67 osteoarthritis patients
68 patches
69 patients
70 penetration
71 penetration capability
72 percutaneous absorption
73 percutaneous absorption ratio
74 pharmacokinetics
75 plasma concentrations
76 plasma pharmacokinetics
77 plaster
78 purpose
79 ratio
80 study
81 superior percutaneous absorption
82 surgery
83 synovial concentrations
84 synovial fluid
85 synovial tissue
86 tape-type patch
87 time
88 tissue
89 tissue penetration
90 tissue penetration capability
91 topical application
92 total knee arthroplasty
93 treatment
94 volunteers
95 schema:name Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans
96 schema:pagination 53-59
97 schema:productId N4b4880e97a6c4cef86942e15032f388d
98 N8fb83cfccc814bd58919c1dfeb7ca0a8
99 Nff47fabc919a424b977a9e6e3d3e16c4
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053196530
101 https://doi.org/10.1007/s00228-015-1960-6
102 schema:sdDatePublished 2022-01-01T18:35
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N66c036365c844eb1b9a4765a94d9d14f
105 schema:url https://doi.org/10.1007/s00228-015-1960-6
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N09e5b8949b2440099898a233054136d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N1b755748b05a40afb9f8fe539ce1d968 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Synovial Membrane
114 rdf:type schema:DefinedTerm
115 N23af7c5088a64db4864c397225394aa6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Adult
117 rdf:type schema:DefinedTerm
118 N3167d6ac7d184188a01c001b810dcbc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 N34f895712bfb4aa7a9277a8312566540 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Anti-Inflammatory Agents, Non-Steroidal
123 rdf:type schema:DefinedTerm
124 N4668d653bebb4bd1b4ed2ba59fa70469 rdf:first sg:person.01172210525.12
125 rdf:rest Ne2f52de5afd54d9c9bc2bf8193e919b2
126 N467fe4b3e4d144a8ab63e2f37aeeec7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Flurbiprofen
128 rdf:type schema:DefinedTerm
129 N4a0860cd8a4c454e98276b34d536145b rdf:first sg:person.01007646725.15
130 rdf:rest Nb86736123e674b2cafa6d10bfde2e584
131 N4b4880e97a6c4cef86942e15032f388d schema:name doi
132 schema:value 10.1007/s00228-015-1960-6
133 rdf:type schema:PropertyValue
134 N4bcdfea986604b38b6eba1062753f971 schema:volumeNumber 72
135 rdf:type schema:PublicationVolume
136 N658eed91326c4e908dd5e3ea525b2985 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Administration, Topical
138 rdf:type schema:DefinedTerm
139 N659ac2300c71410bab7d2ec49b7b3197 rdf:first sg:person.0761060035.15
140 rdf:rest Ncb4bb480aff4475ebb6b455c0e5d5f82
141 N66c036365c844eb1b9a4765a94d9d14f schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N78c9864a542d4a48a203a82c22d7fe4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Transdermal Patch
145 rdf:type schema:DefinedTerm
146 N80d39d3d1e0d4eb1967753239d58deea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Male
148 rdf:type schema:DefinedTerm
149 N832e39b24e5443d4a0614ac3b82a3fbf rdf:first sg:person.01167422121.23
150 rdf:rest rdf:nil
151 N8d212285438b4039ba4c71b01a18a0a9 schema:affiliation grid-institutes:None
152 schema:familyName Sasaki
153 schema:givenName Sigeru
154 rdf:type schema:Person
155 N8fb83cfccc814bd58919c1dfeb7ca0a8 schema:name pubmed_id
156 schema:value 26438533
157 rdf:type schema:PropertyValue
158 N9b651202a74045518af3ef3383cd2e73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Healthy Volunteers
160 rdf:type schema:DefinedTerm
161 N9f04746bbc5347a993ff1567355f87ca schema:issueNumber 1
162 rdf:type schema:PublicationIssue
163 Na0af97498d0c4c82aaebf4f3aa9c1c84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Young Adult
165 rdf:type schema:DefinedTerm
166 Nad0cf376c348409b81aa73aae6073365 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Osteoarthritis, Knee
168 rdf:type schema:DefinedTerm
169 Nb47bc7d12a5f4aed8dbae5ef2cedafbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Aged
171 rdf:type schema:DefinedTerm
172 Nb86736123e674b2cafa6d10bfde2e584 rdf:first sg:person.01055762125.45
173 rdf:rest Nd24d39a2350f4b13a6e40bcb83f35f7d
174 Nc17ed824cf5b4d9884f5d8fb251ea630 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Single-Blind Method
176 rdf:type schema:DefinedTerm
177 Ncb4bb480aff4475ebb6b455c0e5d5f82 rdf:first sg:person.01012703556.79
178 rdf:rest N832e39b24e5443d4a0614ac3b82a3fbf
179 Nd24d39a2350f4b13a6e40bcb83f35f7d rdf:first sg:person.014133260061.74
180 rdf:rest N4668d653bebb4bd1b4ed2ba59fa70469
181 Ne1b81bba59954ecdaeb76288db9a9805 rdf:first N8d212285438b4039ba4c71b01a18a0a9
182 rdf:rest N659ac2300c71410bab7d2ec49b7b3197
183 Ne2f52de5afd54d9c9bc2bf8193e919b2 rdf:first sg:person.0665124056.31
184 rdf:rest Ne1b81bba59954ecdaeb76288db9a9805
185 Nf703805a1a8347f48d6ae0a3f7fc42eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Aged, 80 and over
187 rdf:type schema:DefinedTerm
188 Nfe54a6f261134c2b8ac6800d5594741d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Female
190 rdf:type schema:DefinedTerm
191 Nff47fabc919a424b977a9e6e3d3e16c4 schema:name dimensions_id
192 schema:value pub.1053196530
193 rdf:type schema:PropertyValue
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
198 schema:name Clinical Sciences
199 rdf:type schema:DefinedTerm
200 sg:journal.1054337 schema:issn 0031-6970
201 1432-1041
202 schema:name European Journal of Clinical Pharmacology
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01007646725.15 schema:affiliation grid-institutes:grid.419836.1
206 schema:familyName Yataba
207 schema:givenName Ikuko
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007646725.15
209 rdf:type schema:Person
210 sg:person.01012703556.79 schema:affiliation grid-institutes:grid.26091.3c
211 schema:familyName Matsumoto
212 schema:givenName Hideo
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012703556.79
214 rdf:type schema:Person
215 sg:person.01055762125.45 schema:affiliation grid-institutes:grid.419836.1
216 schema:familyName Otsuka
217 schema:givenName Noboru
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055762125.45
219 rdf:type schema:Person
220 sg:person.01167422121.23 schema:affiliation grid-institutes:grid.410804.9
221 schema:familyName Hoshino
222 schema:givenName Yuichi
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167422121.23
224 rdf:type schema:Person
225 sg:person.01172210525.12 schema:affiliation grid-institutes:grid.418306.8
226 schema:familyName Kamezawa
227 schema:givenName Miho
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172210525.12
229 rdf:type schema:Person
230 sg:person.014133260061.74 schema:affiliation grid-institutes:grid.419836.1
231 schema:familyName Matsushita
232 schema:givenName Isao
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133260061.74
234 rdf:type schema:Person
235 sg:person.0665124056.31 schema:affiliation grid-institutes:grid.418306.8
236 schema:familyName Yamada
237 schema:givenName Ichimaro
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665124056.31
239 rdf:type schema:Person
240 sg:person.0761060035.15 schema:affiliation grid-institutes:grid.440938.2
241 schema:familyName Uebaba
242 schema:givenName Kazuo
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761060035.15
244 rdf:type schema:Person
245 sg:pub.10.1007/s00167-013-2408-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013794139
246 https://doi.org/10.1007/s00167-013-2408-0
247 rdf:type schema:CreativeWork
248 sg:pub.10.1208/s12249-009-9367-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042774560
249 https://doi.org/10.1208/s12249-009-9367-2
250 rdf:type schema:CreativeWork
251 grid-institutes:None schema:alternateName Sapporo Tsukisamu Chuo Orthopedics, Sapporo, Japan
252 schema:name Sapporo Tsukisamu Chuo Orthopedics, Sapporo, Japan
253 rdf:type schema:Organization
254 grid-institutes:grid.26091.3c schema:alternateName Institute for Integrated Sports Medicine, School of Medicine, Keio University, Tokyo, Japan
255 schema:name Institute for Integrated Sports Medicine, School of Medicine, Keio University, Tokyo, Japan
256 rdf:type schema:Organization
257 grid-institutes:grid.410804.9 schema:alternateName Orthopedics Surgery, School of Medicine, Jichi Medical University, Shimotsuke, Japan
258 schema:name Orthopedics Surgery, School of Medicine, Jichi Medical University, Shimotsuke, Japan
259 rdf:type schema:Organization
260 grid-institutes:grid.418306.8 schema:alternateName Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
261 schema:name Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
262 rdf:type schema:Organization
263 grid-institutes:grid.419836.1 schema:alternateName Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan
264 schema:name Development Headquarters, Taisho Pharmaceutical Co. Ltd, 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633 Japan
265 rdf:type schema:Organization
266 grid-institutes:grid.440938.2 schema:alternateName Faculty of Health Science, Teikyo Heisei University, Ichihara, Japan
267 schema:name Faculty of Health Science, Teikyo Heisei University, Ichihara, Japan
268 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...